GLYX-13: Additional Phase IIb data

Additional data from 160 patients who responded to GLYX-13 during the 6-week stabilization period and were re-randomized in the double-blind, U.S. Phase IIb trial showed that IV GLYX-13 weekly missed the primary endpoint of improving clinical response, defined

Read the full 384 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE